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ABSTRACT
Background: The replication and transcription activator (RTA) of Kaposi’s sarcoma-associated herpesvirus (KSHV) is
a molecular switch that initiates a productive replication of latent KSHV genomes. KSHV RTA (K-RTA) is composed
of 691 amino acids with high Ser and Thr content (17.7%), but to what extent these Ser and Thr are modified in
vivo has not been explored.
Methods: By using tandem mass spectrometric analysis of affinity-purified FLAG tagged K-RTA, we sought to
identify Ser and Thr residues that are post-translationally modified in K-RTA.
Results: We found that K-RTA is an O-GlcNAcylated protein and Thr-366/Thr-367 is the primary motif with O-
GlcNAcylation in vivo. The biological significance of O-GlcNAc modified Thr-366 and Thr-367 was assessed by site-
specific amino acid substitution. Replacement of Thr with Ala at amino acid 366 or 367 caused a modest
enhancement of K-RTA transactivation activity in a luciferase reporter assay and a cell model for KSHV reactivation.
By using co-immunoprecipitation coupled with western blot analysis, we showed that the capacity of K-RTA in
associating with endogenous PARP1 was significantly reduced in the Thr-366/Thr-367 O-GlcNAc mutants. PARP1 is
a documented negative regulator of K-RTA that can be ascribed by the attachment of large negatively charged
polymer onto K-RTA via PARP1’s poly (ADP-ribose) polymerase activity. In agreement, shRNA-mediated depletion of
O-GlcNAc transferase (OGT) in KSHV infected cells augmented viral reactivation and virus production that was
accompanied by diminished K-RTA and PARP1 complexes.
Conclusions: KSHV latent-lytic switch K-RTA is modified by cellular O-GlcNAcylation, which imposes a negative
effect on K-RTA transactivation activity. This inhibitory effect involves OGT and PARP1, two nutritional sensors
recently emerging as chromatin modifiers. Thus, we speculate that the activity of K-RTA on its target genes is
continuously checked and modulated by OGT and PARP1 in response to cellular metabolic state.
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Background
The replication and transcription activator K-RTA (also
known as ORF50 or Lyta) is the immediate-early protein
of Kaposi’s sarcoma-associated herpesvirus (KSHV) that
orchestrates and completes a KSHV lytic cycle of repli-
cation in many cell backgrounds. Genetic knockout of
K-RTA resulted in a null phenotype in viral DNA synth-
esis and in virus production [1], emphasizing the
essential role of K-RTA in the course of KSHV latent-
lytic conversion. K-RTA interacts with and is regulated
by a variety of host factors for its full functionality. Spe-
cifically, mutations or deletions introduced in the
responsive elements present in the viral genome of K-
RTA’s interacting partners Oct-1 [2], RBPJ [3] or C/
EBPa [4] impaired K-RTA-mediated viral gene expres-
sion, suggesting these molecules are positive regulators
of K-RTA. By contrast, interactions with host factors
hKFC, PARP1 [5], K-RBP [6] or TLE2 [7] were reported
to reduce K-RTA biological activities, indicating these
molecules are negative regulators. How these regulators
work in concert to determine the activity of K-RTA, and
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ultimately the fate of KSHV infection is of great interest
in this field.
First discovered by Hart and colleagues in 1984 [8], O-
GlcNAcylation is one of the most common post-transla-
tional modifications existing in numerous nucleoplasmic
proteins. Distinct from N-linked glycosylations, which
are found frequently in elongated forms attaching to
extracellular glycoproteins, O-GlcNAcylation involves
the addition of a single N-acetylglucosamine moiety
onto the hydroxyl group of Ser or Thr residues, formally
known as O-linked b-N-acetylglucosamine (O-GlcNAc).
O-GlcNAcylation is a dynamic process that is catalyzed
by O-GlcNAc transferase (OGT) and reversed by O-
GlcNAcase (also known as OGA, NCOAT, MGEA5)
[9]. Because both O-GlcNAcylation and O-phosphoryla-
tion act on the side chains of Ser and Thr residues,
interplays between the two reactions have long been
suspected. It has now been confirmed that crosstalk
between O-GlcNAcylation and O-phosphorylation is not
only active but also multifaceted. First, the turnover
rates of O-GlcNAc and O-phosphate are very similar
[10]. Second, OGT coexists with protein phosphatase
1b/g in a functional complex [11]. Third, large-scale
proteomic analysis revealed that the crosstalk between
O-GlcNAcylation and O-phosphorylation can be derived
from direct competition for a structural occupancy or
by alteration of each other’s enzyme activity via recipro-
cal modifications [12].
O-GlcNAcylation also plays a crucial role in transcrip-
tional regulation. First of all, a great number of factors
in the transcription machinery, including RNA polymer-
ase II and transcription factors, are modified by O-
GlcNAc [9]. In addition, OGT is known to tightly
associate with the mSIN3A-HDAC complex [13].
Recently, Drosophila OGT was found to be a product of
Polycomb group gene, sxc, and was involved in epige-
netic gene silencing [14,15]. Furthermore, Myers et al.
showed that a correct cellular level of O-GlcNAc was
required for a proper transcriptional repertoire in
mouse embryonic stem cells during early development
[16]. It bears to note that O-GlcNAcylation-mediated
transcriptional regulation can convey either a positive or
a negative effect depending on the promoter context
and cell system.
PARP1 is a transferase that adds to proteins the nega-
tively charged polymer ADP-ribose (PAR) from NAD+.
In response to DNA strand breaks, the catalytic activity
of PARP1 is rapidly stimulated and robustly PARylates
itself and various target proteins including core and lin-
ker histones, DNA-PK, topoisomerase I and transcrip-
tion factors. Because the size and large negative charge
of PAR, the addition of PAR may alter the function of
target proteins, including enzymatic activity and pro-
tein-DNA interactions. For example, auto-PARylated
PARP1 loses its affinity with DNA and dissociates from
the chromosome, which allows the access of other DNA
repair enzymes to the injured lesions [17,18]. In addition
to DNA breaks, PARP1 also binds to special DNA struc-
tures including crossovers, cruciforms and supercoils.
With this regard, PARP1 binds to KSHV terminal
repeat/OriP and is linked to viral latent genome mainte-
nance [19].
Previously, by mass spectrometric analysis of affinity-
purified K-RTA proteins, we identified two major modi-
fication sites on K-RTA: one was located at Thr-513
and Thr-514 that involved protein phosphorylation [20]
and the other one was located at Thr-366 and Thr-367
that was O-GlcNAc modified. Here, we began with
focusing on the role of O-GlcNAcylated Thr-366 and
Thr-367 in K-RTA activity. We observed that O-GlcNA-
cylation state of K-RTA was reversely correlated with its
transactivation activity. This inhibition might result
from the recruitment of PARP1 by O-GlcNAcylated K-
RTA. We also noticed that the level of cellular OGT
was reversely related to the amplitude of KSHV lytic
cycle reactivation. Thus, our findings suggest that host




D-(+)-glucosamine hydrochloride (G1514; Sigma), N-
acetyl-D-glucosamine (GlcNAc, A8625, Sigma), O-(2-
acetamido-2-deoxy-D-glucopyranosylidene)amino-N-
phenylcarbamate (PUGNAc, A157250, Toronto
Research Chemicals). Antibodies used in this study were
M2-FLAG (F1804, Sigma), b-actin (A5441, Sigma), OGT
(sc-74546, Santa Cruz Biotechnology, Inc.), PARP1 (sc-
7150, Santa Cruz), GAPDH (#54593, AnaSpec, Inc.), a-
tubulin (Millipore), RL2 (MA1-072, Affinity BioRea-
gents), CTD110.6 (MMS-248R, Covance). Mouse mono-
clonal antibody of K-RTA was obtained from Dr. Keiji
Ueda at Osaka University Graduate School of Medicine,
Japan. Rabbit polyclonal antibody of K-RTA was
obtained from Dr. Yoshihiro Izumiya at University of
California, Davis. Rabbit polyclonal antibody of K-bZIP
was obtained from Dr. Mengtao Li at School of Dentis-
try, University of California, Los Angeles.
Plasmids
pLenti4-Flag-CPO and pLenti4-Flag-Luc were kindly
provided by Dr. Dan Robinson at MCTP, University of
Michigan (Ann Arbor, MI). pLenti4-Flag-CPO is a mod-
ified vector derived from pLenti4/TO/V5-DEST (Invitro-
gen). Briefly, the original attR1 site to V5 epitope region
(nt 2405-4203) in pLenti4/TO/V5-DEST was replaced
with an in-frame DNA fragment encoding Kozak
sequence, ATG, FLAG tag and a rare cutter CPO I site
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(5’CGGTCCG). pLenti4-Flag-KRTA was constructed by
cloning the coding sequences of K-RTA (GeneID:
4961526; Genebank: U71367.1) into the CPO I site of
pLenti4-Flag-CPO. The expression plasmids for T366A,
T367A and T366A/T367A were derived from pLenti4-
Flag-KRTA by using QuikChange® site-directed muta-
genesis kit (Stratagene) with appropriate primers. In
luciferase reporter assays, the upstream sequences of
PAN (nt 28159 to 28660 of U75698) and ORF57 (nt
81556 to 82005) were cloned into Sac I-Xho I sites of
pGL3-Basic (Promega), yielding pGL3-Basic-PANp and
pGL3-Basic-ORF57p, respectively.
Establishment of 293TetKR cells
T-REx™ HEK293 cells (Invitrogen) were infected with
lentivirions harboring pLenti4-Flag-KRTA by using Vira-
Power™ system (Invitrogen). Forty-eight h after infec-
tion, the cells were selected with 400 μg/ml zeocin
(Invitrogen) for two weeks. Zeocin-resistance clones
were subjected to doxycycline (Clontech)-inducibility
test for the expression of desired gene by western blot
analysis using anti-FLAG M2 antibody (Sigma). Two
independent positive clones of K-RTA with similar
growth rate and expression level were pooled, desig-
nated as 293TetKR.
Cell culture
Tet-inducible cell lines 293TetKR and ERKV [21] were
maintained in DMEM supplemented with 10% Tet Sys-
tem Approved FBS (Clontech), 5 μg/ml blasticidin and
200 μg/ml zeocin. HEK293 and 293/rKSHV.219 were
maintained in DMEM with 10% FBS (Invitrogen). Puro-
mycin (660 ng/ml, BD Biosciences) was added to the
culture media of ERKV and 293/rKSHV.219 cells for the
maintenance of viral genomes. On a routine basis, all
cells were maintained in a humidified 37°C incubator
with 5% CO2, passaged and fed every 3 to 4 days.
Protein purification
Immuno-purification of FLAG-tagged protein from
293Tet-inducible cell line was carried out according to
two previously described procedures [22,23] with minor
modifications. Specifically, one hundred million cells
with 80% confluence were treated with 50 ng/ml doxy-
cycline for 5 h and doxycycline plus 10 mM glucosa-
mine for additional 5 h before cell harvest. Combined
cell pellet (~ 1 g) was solubilized in 10 ml lysis buffer
(50 mM Tris-HCl, pH 7.4, 100 mM GlcNAc, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 1 × protease inhi-
bitors, 0.2 mM sodium orthovanadate) at 4°C for 40 min
with gentle shaking. Protein extracts were clarified by
centrifugation at 12,000 × g, 4°C for 15 min. Collected
protein supernatant was filtrated through a 0.45 micron
filter to remove cell debris. The filtered protein
supernatant was applied onto 400 μl anti-FLAG M2 affi-
nity resin (A2220, Sigma) equilibrated with lysis buffer.
The column eluate was re-loaded onto the column for
two more cycles. The column was alternatively washed
with one column volume of TBS (50 mM Tris-HCl, pH
7.4, 150 mM NaCl) followed by one column volume of
high salt (500 mM NaCl)-TBS for three times. The col-
umn was washed with additional two column volumes
of TBS buffer prior to elution. The FLAG-tagged protein
was eluted from the column by TBS buffer supplemen-
ted with 100 μg/ml FLAG peptide (F3290; Sigma) and
20% glycerol. For each purification, four eluted fractions
were collected and samples were immediately frozen in
-70°C for further studies.
Liquid chromatography-tandem mass spectrometry (LC-
MS/MS)
The affinity purified K-RTA (~500 ng) was resolved in
8% SDS-PAGE followed by SYPRO® Ruby (Invitrogen)
staining. Stained region was excised and in-gel digested
with trypsin (sequencing grade, Promega). The digests
were first mapped by MALDI-MS analysis on an ABI
4700 Proteomics Analyzer to identify candidate O-
GlcNAc modified K-RTA peptide, which was indicated
by the presence of molecular ion signal at 204 Da above
the identified tryptic peptide signal. The sample was
then subjected to LC-MS/MS analysis as described pre-
viously [24] to confirm and identify the O-GlcNAcylated
sites.
Transfection and luciferase reporter assay
Transfection was performed in 24-well plates. HEK293
cells (2.5 × 105) were seeded into each well to reach a
90% confluence the next day before transfection. Trans-
fection was carried out using Lipofectamine™ 2000
(Invitrogen) conveying appropriate plasmids according
to the manufacturer’s instruction. Twenty-four h after
transfection, cells were harvested for luciferase activity
assay. Transfection efficiency was normalized by a co-
transfected renilla luciferase reporter (phRL-TK, Pro-
mega). Firefly and renilla luciferase activities were mea-
sured by an Orion L Luminometer (Berthold Detection
Systems) using Dual-Glo luciferase assay kit (Promega).
Western blot analysis and co-immunoprecipitation
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 8,
100 mM GlcNAc, 150 mM NaCl, 0.1% Nonidet P-40,
0.5% sodium deoxycholate, 0.1% SDS, 1 mM phenyl-
methylsulfonyl fluoride, 0.2 mM sodium orthovanadate,
1 × protease and 1 × phosphatase inhibitors). The pro-
tein concentration was measured spectrophotometrically
at 562 nm using BCA protein assay reagent (Pierce). For
each co-immunoprecipitation assay, cells were lysed in
cold EBC lysis buffer (50 mM Tris-HCl, pH 7.8, 100
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mM GlcNAc, 120 mM NaCl, 0.5% NP-40, 50 mM NaF,
1 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium
orthovanadate, and 1 × protease inhibitors). Three hun-
dred μg protein was mixed with pre-washed anti-FLAG
M2 affinity beads on a nutator mixer overnight at 4°C.
After centrifugation, the resin was washed thoroughly
with TBS three times followed by elution of immuno-
complex in 1 × sample buffer. Cell lysates or the eluted
immunocomplex were subjected to SDS-PAGE separa-
tion and analyzed by western blotting as described pre-
viously [21].
Immunofluorescence assay
HEK293 cells at a density of 105/0.4 ml/well were
seeded onto a 8-well chamber slide (Nunc) coated with
poly-D-Lysine (Sigma) overnight. The cells were trans-
fected with indicated plasmids using Lipofectamine™.
2000 (Invitrogen) according to the manufacturer’s
instructions. Twenty-four h after transfection, cells were
fixed with prechilled acetone/methanol (v/v = 1:1) at RT
for 10 min and permeablied with 0.4% Triton X-100 at
RT for 5 min. The slides were blocked for 30 min in
blocking buffer (PBS containing 1% FBS) and incubated
with anti-FLAG antibody (1: 100) in blocking buffer at
RT for 2 h. The slides were washed with PBS three
times for 5 min each. The slides were incubated with
fluorescein isothiocyanate-conjugated anti-mouse IgG
for 1 h and counterstained with DAPI (Sigma) for 5 min
at RT. The slides were observed under a fluorescence
microscope.
Flow cytometric analysis
After transfection, the cells were harvested by trypsiniza-
tion and resuspended in a 500 μl PBS. A total of 10,000
cells were acquired by a flow cytometer (FACSCalibur,
Becton Dickinson) and analyzed using the WinMDI v2.8
software. Signals for green fluorescent protein and red
fluorescent protein were detected at 488 nm and 540
nm, respectively.
Lentivirus-based short hairpin RNAs (shRNA) knockdown
of OGT
Five shRNA clones for each target protein (OGT or
luciferase) were purchased from the National shRNA
Core (Academia Sinica, Taipei, Taiwan). High-titer lenti-
virion for each shRNA clone was prepared according to
the Core’s instruction manual. A pilot study by using
EGFP-lentivirions was conducted to optimize the target
cell plating and growth, viral dose, and assay times. Sub-
sequently, ERKV cells were seeded at a density of 6 ×
105 cells/well in 6-well assay plates, incubated 24 h at
37°C, and infected with indicated lentiviral shRNA
supernatant for 48 h, followed by doxycycline (50 ng/
ml) induction of KSHV reactivation for 48 h before cell
harvest.
Titration of KSHV viral particles
Filtrated (0.45 μm) viral supernatant (160 μl) was incu-
bated with 2 U DNase I (Invitrogen) at 37°C for 30 min
followed by extraction of encapsidated KSHV DNA
using QIAamp MinElute virus spin kit (QIAGEN). Each
comparative quantitative PCR reaction was composed of
4 μl diluted viral DNA, 5 μl Power SYBR Green Master
Mix (Applied Biosystems), and 1 μl primer mix (2 μM).
The primers used in the present study are as follows:
detection of KSHV genome, ORF9-forward (5’-CCAA-
CATCATCCAATGCC TC-3’) and ORF9-reverse (5’-
GGGAAAAGTCACGGGAATG-3’). Known copy num-
bers of serially diluted cosmid GB11 DNA encompassing
KSHV genome nt 1-35,022 (U75698) were used as stan-
dards in titrating KSHV viral particles. The reaction was
conducted and detected by StepOnePlus™ Real-Time
PCR system (Applied Biosystems).
Results
K-RTA possesses 20 potential O-GlcNAcylation residues
293TetKR is a recently established HEK293 cell line that
displays doxycycline (Dox)-controlled, conditional
expression of K-RTA. Expression of K-RTA was induced
by treating 293TetKR cells with low concentration (50
ng/ml) of Dox, a physiologically neutral compound. K-
RTA was detectable at 6 h and was expressed stably
until 96 h in the Dox-treated 293TetKR cells by western
blot analysis (Figure 1A). Removal of Dox from the 24 h
treatment resulted in a near depletion of K-RTA in 15 h
(Figure 1B), indicating that both synthesis and degrada-
tion of K-RTA was active and a continuous supplement
of Dox is required for a sustained expression of K-RTA
throughout the course of experiments. The molecular
weight of K-RTA produced in 293TetKR cells (114 kDa)
was apparently greater than the in vitro-translated spe-
cies (95 kDa, not shown) and its predicted size (76
kDa), suggesting that extensive post-translational modi-
fication products might attach to K-RTA during protein
maturation. K-RTA was previously hypothesized to be
an abundantly phosphorylated protein [25], but the role
of phosphorylation in K-RTA structure and function is
unclear. Interestingly, when we inspected the 137 poten-
tial phosphorylation residues consisted of Ser, Thr and
Tyr, we noticed that there are 20 Thr and Ser exhibiting
a high likelihood for O-GlcNAcylation, and 11 of them
are also potential phosphorylation sites (solid circles,
Figure 1C). These predictions suggested that O-GlcNAc
and O-phosphate might alternate on these Ser and Thr
residues. To assess whether K-RTA is O-GlcNAcylated
in vivo, protein extracts from Dox-treated 293TetKR,
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293TetNLSm and 293TetER [21] were immunoprecipi-
tated with RL2, an antibody specifically recognizing the
O-GlcNAc epitope, followed by western blot analysis
using the M2-FLAG antibody. We found that both K-
RTA and its mutant defective in nuclear localization sig-
nal (NLSm), but not EBV Rta, were recognized by RL2
(Figure 1D), indicating that K-RTA is O-GlcNAcylated.
These preliminary results prompted us to identify the
authentic in vivo O-GlcNAcylation sites in K-RTA by
mass spectrometry.
Identification of Thr-366 and Thr-367 as the primary in
vivo O-GlcNAcylation motif of K-RTA
To identify which of the 20 potential Ser or Thr amino
acids are O-GlcNAcylated in vivo, FLAG-tagged K-RTA
derived from Dox-treated 293TetKR cells was affinity
purified using M2-FLAG resin according to two pre-
viously described procedures [22,23] (Figure 2A). A
portion of the affinity-purified K-RTA was subjected to
western blot analyses using two different O-GlcNAc
antibodies, RL2 and CTD110.6. To rule out the nonspe-
cific cross hybridization that can arise in western blot
analysis, equivalent amounts of purified K-RTA, NLSm,
EBV Rta, rhesus monkey rhadinovirus RTA and bovine
serum albumin were analyzed in parallel. Whereas the
four FLAG-tagged proteins were detected by a-FLAG,
only K-RTA and K-RTA NLSm were immunoreactive to
RL2 and CTD110.6 (Figure 2B), indicating the specificity
of the current procedure. Further, to identify the
authentic O-GlcNAcylation sites conclusively, purified
K-RTA was subjected to LC-MS/MS analysis. As
expected, a strong peak of 204.1 Da in size indicative of
GlcNAc was recognized (Figure 2C, denoted by Hex-
NAc*). The strong oxonium ions at m/z 204, 168 and
138 confirmed the presence of a GlcNAc moiety but the
precise location cannot be established unambiguously
Figure 1 K-RTA, but not EBV Rta, is recognized by the anti-O-GlcNAc antibody RL2. (A) Expression kinetics of K-RTA in Doxycycline (Dox)-
treated 293TetKR cells (50 ng/ml) for the indicated times. C6: untreated 293TetKR at 6 h. (B) Protein stability of K-RTA in 293TetKR cells. The
remaining amounts of K-RTA in 24 h Dox-treated 293TetKR cells were monitored between 4 and 24 h after Dox removal. ST: starting material. (C)
The 20 potential O-GlcNAc sites present in the primary sequence of K-RTA composed of 691 amino acids were identified using the CBS
YinOYang [45] and SVM [46] prediction programs. Ser and Thr residues scored positive in both programs are denoted by circles above the
amino acid symbols. Open circles indicate that residues are only O-GlcNAcylated; solid circles represent residues that might also be
phosphorylated. Thr-366 and Thr-367 are underlined. (D) Protein extracts from 293TetKR (K-RTA), 293TetNLSm (K-RTA defective in nuclear
localization signal) and 293TetER (EBV Rta) cells were immunoprecipitated by an anti-O-GlcNAc antibody (RL2) followed by western blot analysis
using the M2-FLAG antibody. Only K-RTA and NLSm were immunoprecipitated by anti-O-GlcNAc antibody.
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because of facile neutral loss of O-GlcNAc. Nonetheless,
a candidate singly O-GlcNAcylated tryptic peptide
(AVAQGAVITATTVPQAMPAR) was revealed by MS/
MS spectrum and a weak signal at m/z 1290, assigned
to O-GlcNAcylated y10, suggested that the single O-
GlcNAc is most likely attached to Thr-366 or Thr-367.
Finally, the oxidized Met residue contributed to the
observed -64 u loss, which is in accordance with Guan
et al. [26] (Figure 2C). In conclusion, these results estab-
lished that K-RTA is immunoreactive to two distinct O-
GlcNAc antibodies and that an in vivo O-GlcNAc motif
is located at Thr-366/Thr-367.
O-GlcNAcylation of Thr-366 and Thr-367 is suppressive to
the potency of K-RTA mediated viral promoter
transactivation and lytic cycle reactivation
To test whether O-GlcNAcylation of Thr-366/Thr367 is
required for K-RTA’s biological activity, three Thr to
Ala substitution mutants were generated to mimic the
unmodified status of these amino acids (Figure 3A,
upper). We first confirmed that the three variants were
primarily localized in the nucleus using an immuno-
fluorescence assay (Figure 3A, lower). In addition, the
protein expression levels and migration patterns of the
three variants were similar to that of the wild-type K-
Figure 2 Identification by mass spectrometry (MS) of in vivo O-GlcNAc sites in K-RTA. (A) Affinity purification of FLAG-K-RTA by M2-FLAG
resin. Protein extracts from 1 g (~108 cells) of Dox-treated 293TetKR cells were used as starting material. Purification was verified by western blot
analysis using M2-FLAG antibody. ST, starting material; FT, flow through; W, wash; E1-E4, eluted fractions 1-4. (B) Purified K-RTA and K-RTA mutant
defective in nuclear localization signal (NLSm) were readily immunoreactive to the anti-O-GlcNAc antibodies RL2 and CTD110.6. Aliquots of ~ 50
ng of each affinity-purified protein, including K-RTA, K-RTA NLSm (NLSm), EBV Rta (E-RTA), rhesus monkey rhadinovirus RTA (R-RTA) and 300 ng
bovine serum albumin (BSA), were used to prepare one of the three identical immunoblots. The blots were respectively hybridized to anti-FLAG,
RL2 and CTD110.6. Whereas the four FLAG-tagged proteins were obviously detected by anti-FLAG, only K-RTA and NLSm possess O-GlcNAc
epitopes that were detectable by RL2 and CTD110.6. (C) MS/MS spectrum of a candidate singly O-GlcNAcylated tryptic peptide,
AVAQGAVITATTVPQAMPAR, from the E2 fraction of the purified K-RTA (rectangle) at m/z 724.70 (3+). The strong oxonium ions at m/z 204
(HexNAc*), 168 and 138 confirm the presence of GlcNAc moiety but the precise site location cannot be established unambiguously because of
the facile neutral loss of O-GlcNAc (see text).
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RTA (Figure 3B). Next, we wished to compare the trans-
activation activities of wild-type K-RTA and the three
O-GlcNAc site mutants. Two well-established K-RTA
target promoters were used: ORF57 and PAN [27]. The
results from multiple independent assays showed that
although moderate, the substitutions of Thr residues at
T366 and T367 constantly increased the transactivation
activity of K-RTA on both KSHV early promoters (Fig-
ure 3C-D). These results implied that O-GlcNAcylation
of Thr-366 or Thr-367 might inhibit the transactivation
potency of K-RTA. This observation is reminiscent of
the inhibitory effect of O-GlcNAcylation on cellular fac-
tor Sp1 [28,29] and C/EBPb [30].
To extend this study in cells infected with KSHV,
expression plasmids of wild-type K-RTA, T366A, T367A
and T366A/T367A were ectopically expressed in 293/
rKSHV.219 cells, followed by scoring of the percentage
of green and red fluorescence double-positive cells, an
indicator of KSHV lytic reactivation [31]. At a transfec-
tion rate ~80%, lytic reactivation induced by the wild-
type K-RTA was 15-28% less than that by the three
mutants (Figure 4). These results are consistent with
Figure 3 Disruption of O-GlcNAcylation on T366 and T367 leads to an increase in the transactivation activity of K-RTA. (A) Nuclear
localizations of the O-GlcNAc mutants were similar to the wild-type K-RTA, as shown by an immunofluorescence assay using M2-FLAG antibody.
(B) Western blot analysis of protein extracts from HEK293 cells transiently transfected with expression plasmids for K-RTA or O-GlcNAc mutants.
GAPDH served as a loading control. Similar protein expression levels and migration patterns were observed between wild-type K-RTA and the
three O-GlcNAc mutants. (C) Luciferase reporter assay of the KSHV ORF57 promoter responding to K-RTA and O-GlcNAc mutants in HEK293 cells.
Each firefly luciferase value was normalized to an internal control plasmid, pRL-TK. The normalized value for K-RTA was set to 100%. Data are
presented as the mean ± SD from triplicate transfections. * denotes P < 0.05 (Student’s t-test). Six independent experiments were performed and
a representative result is shown. (D) Luciferase reporter assay of the KSHV PAN promoter responding to K-RTA and O-GlcNAc mutants in HEK293
cells. The procedure was carried out as described in (C), except that ORF57p was replaced with PANp. Six independent experiments were
performed and a representative result is shown.
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those from luciferase reporter assays (Figure 3) and
together suggest that O-GlcNAcylation of Thr-366 or
Thr-367 imposes a suppressive effect toward K-RTA
during viral reactivation. It bears noting that, between
Thr-366 and Thr-367, neither luciferase reporter assays
(Figure 3C-D) nor lytic reactivation scoring method
(Figure 4) could conclusively discern which residue is
more important, suggesting that O-GlcNAc could be
dynamically or alternatively added onto these two resi-
dues. In agreement, the double mutant, T366A/T367A,
yielded more consistent and prominent effect in the
aforementioned experiments.
O-GlcNAcylation of Thr-366 and Thr-367 is involved in
PARP1 recruitment
Among various K-RTA interacting cellular proteins, we
were particularly interested in HDAC1 and PARP1
because these two molecules are known negative regula-
tors of transcription [32,33] and have been shown to
repress K-RTA’s activity by Gwack and colleagues
[5,34]. To this end, protein extracts of 293T cells transi-
ently transfected with K-RTA or the three O-GlcNAc
mutants were subjected to co-immunoprecipitation (Co-
IP) assay using M2-FLAG resin. Equal aliquots of the
immunocomplexes from each Co-IP were used to pre-
pare four duplicate immunoblots, delegated for antibo-
dies against FLAG, O-GlcNAc (RL2), HDAC1 and
PARP1. First, the result of M2-FLAG antibody validated
that the Co-IP efficiency of all FLAG-tagged protein
complexes were similar (Figure 5, top panel). Next, the
O-GlcNAcylation states of K-RTA and mutants were
revealed by the O-GlcNAc-specific antibodies RL2 (mid-
dle panel). The degree of O-GlcNAcylation in the three
O-GlcNAc mutants were less than that in the wild-type
K-RTA, reinforcing that this motif is in vivo modified
with O-GlcNAc. Also, the result indicates that there are
additional O-GlcNAcylation sites in K-RTA that were
missed in our mass spectrometric analysis (discussed
below). Importantly, we found that while the amount of
HDAC1 immunoprecipitated in each complex did not
vary significantly (not shown), the amount of PARP1 in
T367A and T366A/T367A was ~70% less than that in
the K-RTA wild-type, suggesting that association of K-
RTA with PARP1 was proportional to the state of O-
GlcNAcylation (Figure 5, bottom panel). Taken together,
these results suggested that O-GlcNAcylation of K-RTA
facilitates its recruitment of negative regulator PARP1,
which in turn dampens K-RTA activity (Figure 3, 4).
Depletion of OGT resulted in increased KSHV reactivation
Given that T366A/T367A mutant is still detectable by
a-O-GlcNAc antibody and associates with PARP1 (Fig-
ure 5), it is imprudent to use this mutant as a un-glyco-
sylated form of K-RTA. In addition, pilot experiments
showed that both wild-type K-RTA and O-GlcNAc var-
iants, when provided ectopically, could induce the
expression of endogenous K-RTA in a given KSHV-
positive cell. This endogenous K-RTA then took over
the reactivation process by which the initial effects of
wild-type K-RTA and O-GlcNAc mutants became less
distinguishable. Thereby, to explore the biological
impacts of O-GlcNAcylation on K-RTA in KSHV-
Figure 4 O-GlcNAcylation of Thr-366 and Thr-367 is involved in KSHV reactivation. (A) Comparison by flow cytometric analysis of the
potency for viral latency disruption of K-RTA and O-GlcNAc mutants. 293/rKSHV.219 cells transfected with K-RTA or the three O-GlcNAc mutants
(T366A, T367A and T366A/T367A) for 72 h were analyzed on a fluorescence-activated cell sorter followed by scoring the percentage of double
positive (GFP and RFP) cells in each population, as indicated in the upper right of each panel. Untreated cells (293/KSHV) served as a control. (B)
A schematic chart summarizes the results derived from eight independent experiments. Data are presented as the mean ± SD with the K-RTA
group set to 100%. * denotes P < 0.05 (Student’s t-test).
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infected cells, we asked whether global decrease of O-
GlcNAcylation by short hairpin RNAs (shRNA) knock-
down of OGT would affect K-RTA mediated KSHV
reactivation. To this end, shRNAs of control luciferase
(shLuc) or OGT (shOGT) were delivered into ERKV
cells for 48 h. ERKV is a recently established cell model
by which reactivation of KSHV could be homogeneously
induced by low concentration of doxycycline (Dox, 50
ng/ml) [21]. To validate the shRNA knockdown effi-
ciency, the global O-GlcNAcylation state of ERKV cells
receiving shLuc or shOGT were measured by western
blot analysis using O-GlcNAc antibody RL2. As
expected, shOGT noticeably decreased the overall O-
GlcNAcylation state in ERKV cells (Figure 6A). Another
O-GlcNAc antibody CTD110.6 also gave same result
(not shown).
To evaluate the extent of KSHV lytic cycle reactiva-
tion under hypo-O-GlcNAcylation states, shLuc or
shOGT-expressing ERKV cells were treated with Dox
for 48 h, and the protein extracts of each sample were
subjected to western blot analysis or immunoprecipita-
tion assay. To examine the nature of K-RTA and
PARP1 complexes in these shOGT-expressing cells, pro-
tein extracts of shLuc or shOGT-expressing cells were
immunoprecipitated by a-K-RTA followed by western
blot analysis using a-K-RTA and a-PARP1, respectively.
As depicted in Figure 6B, despite more K-RTA was
synthesized in the shOGT-expressing cells, a feature can
be attributed by a positive feedback of K-RTA auto-reg-
ulation [35], the amount of PARP1 interacting with K-
RTA was dramatically reduced in the shOGT cells. This
data is consistent with previous findings that Thr-366/
Thr-367 O-GlcNAc mutants associated with less PARP1
(Figure 5) and were more potent (Figure 3-4). Next,
because K-bZIP is a direct downstream target of K-
RTA, expression of K-bZIP was used as a surrogate
marker for K-RTA mediated viral reactivation. As
shown in Figure 6C, expression of K-bZIP was elevated
in shOGT cells relative to that in the control group.
Furthermore, we observed that K-bZIP expression was
inversely correlated with the level of OGT in multiple
independent experiments using different sets of shOGT
RNAs (Figure 6C and data not shown), indicating that
hypo-O-GlcNAcylation is a favorable environment for
KSHV lytic cycle reactivation. This notion is further
supported by a parallel increased titer of viral particles
shed into the culture medium (Figure 6C). Taken
together, based on these results we propose that during
KSHV lytic cycle replication, more OGT will facilitate
the O-GlcNAcylation state of K-RTA that in turn
recruits more PARP1 and diminish the potency of K-
RTA.
Discussion
K-RTA is a Ser and Thr-rich protein (122 out of 691
amino acids, 17.7%) but the sites and roles of post-
translational modifications (PTMs) on these residues are
largely unexplored. In this study, by using mass spectro-
metric analysis we demonstrated that K-RTA is an O-
GlcNAcylated protein and that Thr-366/Thr-367 is an
O-GlcNAcylation motif. Thr to Ala mutations at this
motif increased K-RTA’s transactivation capability in
luciferase reporter assays and KSHV reactivation in 293/
rKSHV.219 cells, indicating that O-GlcNAcylation may
impose a suppressive effect on K-RTA. This notion was
further supported by increased K-bZIP expression and
viral particle production in KSHV infected cells depleted
with O-GlcNAc transferase (OGT). The inhibitory effect
of O-GlcNAcylation on K-RTA was attributed to an
increasing affinity between glycosylated K-RTA and
PARP1. Noteworthy, PARylation of K-RTA by PARP1
was previously shown to negatively modulate the activity
of K-RTA [5]. Thereby, our results established a link
between these two PTMs in regulating K-RTA. Further-
more, given that O-GlcNAcylation is a dynamic process
keenly responding to glucose fluctuation, we speculate
that the activity of K-RTA is closely controlled by the
metabolic state of the host cell. For example, Delgado et
al. recently demonstrated that induction of Warburg
effect in KSHV-latently infected endothelial cells is a
Figure 5 O-GlcNAcylation of Thr-366 and Thr-367 plays a role
in PARP1 recruitment. Protein extracts from 293T cells transiently
transfected with plasmids expressing K-RTA or O-GlcNAc mutants
for 24 h were subjected to co-immunoprecipitation (Co-IP) assays
by using M2-FLAG resins. Equal aliquots of each Co-IP were resolved
on SDS-PAGE followed by western blot analysis using indicated
antibodies. After normalized to respective total IP proteins (a-FLAG),
the relative ratios of O-GlcNAcylation state (a-RL2) and the amount
of PARP1 recruited by K-RTA and O-GlcNAc mutants are denoted
beneath each lane.
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required process for tumor cell survival [36]. As
increased glucose uptake will produce more UDP-
GlcNAc, in theory Warburg effect would be coupled
with elevated O-GlcNAcylation. Thus, Warburg effect
may create an environment suppressive to K-RTA’s full
functionality that leads to a crippled KSHV reactivation.
This could explain why most KSHV remain latent in the
KS biopsies.
In Figure 5, the M2-FLAG resin-precipitated T366A/
T367A mutant is still reactive to a-O-GlcNAc antibody
(RL2), indicating that Thr-366/Thr-367 is not the only
site modified by O-GlcNAc. This partial de-O-
GlcNAcylation in Thr-366 and Thr-367 mutants may
explain why the enhancement effects in our functional
assays were small, although statistically significant (Fig-
ure 3, 4). We reasoned that those unidentified O-
GlcNAcylation sites most likely are located at larger
tryptic peptides that have been excluded in our mass
spectrometry (e.g., amino acids 531-633, approximately
10.6 kDa, contain 25 Ser/Thr). Alternatively, the fragile
O-GlcNAc moieties might have been lost during protein
purification. Thus, the use of other proteases such as
chymotrypsin to supplement the trypsin digestion, or
employing more advanced methods including “QUICK-
Figure 6 Depletion of O-GlcNAc transferase (OGT) led to enhancement of KSHV reactivation. Lentivirus-based short hairpin RNAs (shRNA)
targeting luciferase (Luc), or OGT were expressed in ERKV cells for 48 h, followed by doxycycline (50 ng/ml)-induction of KSHV reactivation for
additional 48 h. (A) Western blot analysis of protein extracts from shRNA-treated cells by using a-O-GlcNAc antibody (RL2). Compared to control
shLuc, shOGT decreases the global O-GlcNAcylation state in ERKV cells. b-actin served as a loading control. (B) K-RTA interacts with less PARP1 in
shOGT-treated ERKV cells. Protein extracts from shRNA-treated ERKV cells were subjected to co-immunoprecipitation (Co-IP) assay using a-K-RTA
antibody. Equal aliquots of each Co-IP were resolved on SDS-PAGE followed by western blot analysis using indicated antibodies. (C) (upper)
Western blot analysis of K-bZIP and OGT expressions in shRNA-treated ERKV cells. An enhanced expression of K-bZIP is present in the OGT
knockdown cells relative to that in the control shLuc group. The expression pattern of K-bZIP is inversely correlated with the cellular OGT level.
a-tubulin served as a loading control. (lower) KSHV particles released from shLuc and shOGT-treated ERKV cells. Copy numbers of DNase I-
resistant, encapsidated viral DNAs in each filtrated culture supernatants were determined by comparative quantitative PCR of KSHV DNA
polymerase gene (ORF9). Data are presented as means ± SD from three PCR assays in an experiment. Similar results were obtained from two
independent experiments; one set of data is shown.
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Tag” and electron transfer dissociation mass spectrome-
try [37,38] should disclose additional O-GlcNAcylation
sites in K-RTA and provide a more comprehensive bio-
logical relevance.
Suppression of transactivation activity by O-GlcNAcy-
lation is best known in Sp1. An O-GlcNAcylated activa-
tion domain of Sp1 repelled its hydrophobic interaction
with TAF110 in vitro [29] and removal of the O-GlcNAc
moiety in Sp1 elicited a signal for activation [29,39].
Hyper-O-GlcNAcylation of Sp1 severely impaired the
transactivation of p21/WAF1 promoter in HeLa cells
[28], and, the LTR promoter activity of HIV-1 in T cells
[40]. Other than Sp1, O-GlcNAcylation of C/EBPb, YY1
and NF-B p65 also brought suppressive transcriptional
effects on their target genes [30,41,42]. Here, we showed
that forced de-O-GlcNAcylation of Thr-366 and Thr-
367 in K-RTA resulted in moderate enhancement in
activity (Figure 3, 4). This motif is located in the middle
of the 691 amino acids consisting of K-RTA, a region
previously mapped to interact with positive regulator
RBPJ [3]. Thus, it is likely that unmodified Thr-366/
Thr-367 in this region may provide a better interaction
domain for RBPJ or factors in the transcription
machinery, as has been described in the case of Sp1. In
addition, we found that O-GlcNAcylated K-RTA
“attracts” more PARP1, another kind of PTM enzyme
that transfers large and negatively charged polymer
(PAR) onto numerous nuclear factors. Frequently, the
attachment of PAR led to altered activity and function
of target proteins through both steric and charge inhibi-
tion [17]. In agreement, a previous report demonstrated
that PARP1 PARylated K-RTA in vitro and suppressed
its activity in a co-expression assay [5]. Combined, we
speculate that O-GlcNAcylated K-RTA repels more of
its positive regulators, associates with more PARP1 thus
being PARylated, and ultimately its full functionality is
restricted. It would be of great interest to investigate
whether O-GlcNAcylation and PARylation exert syner-
gistic or feedback effects in modulating K-RTA.
O-GlcNAcylation-mediated transcriptional suppression
could also take place at the chromatin level. First discov-
ered by Yang et al., OGT was targeted by mSin3A and
participated in gene silencing [13]. Drosophila OGT was
found to be encoded by Polycomb group gene, super sex
combs (sxc), and directly participated in epigenetic gene
silencing on polytene chromosomes [14,15]. In mammals,
murine OGT stability was regulated by polycomb repres-
sive complex 2 and the cellular O-GlcNAc level was cru-
cial to the transcription repertoire in embryonic stem
cells [16]. Together, these findings provide a new per-
spective that OGT could be an authentic chromatin
remodeller. Indeed, O-GlcNAcylation of H2B facilitates
its subsequent monoubiquitination [43] and in vivo O-
GlcNAcylation sites of other histone members have been
revealed [44]. Intriguingly, to add one more layer of
complexity, the role of PARP1 in chromatin structure
modification is also increasingly evident [17]. Thereby,
it is tempting to propose that modification of K-RTA
by OGT and interaction of K-RTA with PARP1 may
be only the secondary events. Targeting by K-RTA,
OGT and PARP1 may actively modify the viral genome
structures at epigenetic level before decorate and
oppress K-RTA function. With this regard, future
experiments are required to delineate the spatiotem-
poral occupancies of OGT, PARP1 and K-RTA on the
viral genome and their relevance to K-RTA mediated
latent-lytic switch.
We began our study by computational analysis of K-
RTA primary amino acid sequences, realized that 11 of
the 20 potential O-GlcNAcylation sites could also be O-
phosphorylated (Figure 1C). Thr-367 is one of them.
Interestingly, although our mass spectrometry did not
resolve whether Thr-366 or Thr-367 is morel likely to
be the real acceptor for O-GlcNAc, in Figure 5, substitu-
tion of Thr to Ala at Thr-367 seemed to cause a more
distinct phenotype than substitution introduced at Thr-
366. Thus, these hypothetical sites could serve as a blue-
print for further studies in understanding alternate mod-
ifications of O-GlcNAcylation and O-phosphorylation in
K-RTA.
Conclusions
We identified Thr-366/Thr-367 in K-RTA is an in vivo
O-GlcNAcylated motif by tandem mass spectrometric
analysis. We showed that K-RTA with Thr to Ala muta-
tions at 366 and 367 were decorated with less O-
GlcNAc and were more potent. In agreement, forced-
depletion of O-GlcNAc transferase (OGT) during KSHV
lytic cycle replication noticeably enhanced viral lytic
gene expression and viral particle production. The sup-
pressive effect of O-GlcNAcylation on K-RTA was
ascribed by increased capacity in PARP1 association.
Noteworthy, the roles of OGT and PARP1 in chromatin
modification/architecture have recently emerged; indi-
cating that K-RTA mediated gene expression is con-
trolled by chromatin remodeling factors.
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